Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.6 (thromboplastin)
 13,278 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The relationship of serotonin to the inhibition of collateral blood flow was investigated. Five cats, in which the aorta contained a 6 microgram injection of serotonin in a closed aortic segment exhibited depressed hindlimb blood flow. The serotonin effects were eliminated in three animals by pretreatment with cinarserin HCl, a serotonin antagonist. The caudal 1.5 cm of the aorta was occluded in 24 cats by a blood clot formed by injection of thromboplastin subsequent to ligation. Eight of these animals were pretreated with cinanserin HCl and exhibited a significant improvement in hindlimb collateral blood flow. Serotonin was reduced in nine of these animals with reserpine/p-CPA treatment, and they exhibited the most significant recovery of all treated animals. Seven of the cats with blood serotonin reduced by decreasing blood platelets showed no improvement in hindlimb blood flow. The results of this study indicate that serotonin is a factor in the inhibition of collateral blood flow which follows arterial thrombosis.
 ...
PMID:Serotonin as a factor in depression of collateral blood flow following experimental arterial thrombosis. 14 2

We herein report the cases of two elderly patients with acquired hemophilia A (AHA) for whom treatment was difficult.An 89-year-old woman (Case 1) was admitted to our department with subcutaneous hemorrhage and melena. Her activated partial thromboplastin time (APTT), factor VIII activity, and factor VIII inhibitor level were 127.7 seconds, 1.0%, and 48 BU/mL, respectively, which was suggestive of AHA. The administration of prednisolone (PSL 0.5 mg/kg) was initiated. After 3 weeks, PSL was combined with cyclophosphamide (CPA 50 mg). Two months after the start of treatment, her factor VIII inhibitor level decreased to 3.4 BU/mL. However, hemorrhagic signs were repeatedly observed during the discontinuation of recombinant activated factor VII (rFVIIa) preparation; bleeding control became insufficient, and pneumonia developed, thus leading to a fatal outcome.An 81-year-old woman (Case 2) was admitted to our department with subcutaneous hemorrhage, anemia (Hb: 9.2 g/dL), and a prolonged APTT (78.7 seconds). Her factor VIII activity was reduced to 0.9%, and her factor VIII inhibitor level was markedly increased to 1,364.9 BU/mL, suggesting AHA. Treatment with PSL (0.5 mg/kg) was initiated. After one month, it was combined with CPA (50 mg); however, her hemorrhagic signs were protracted, and her Hb level decreased to 8.0 g/dL. Subsequently, pneumonia occurred. However, weekly rituximab therapy (375 mg/m2) for 4 weeks decreased her factor VIII inhibitor level, leading to the disappearance of the inhibitor at 1 year and 5 months. During this period, there were no episodes requiring the administration of bypassing agents, such as rFVIIa.
 ...
PMID:Two elderly patients with difficult-to-treat acquired hemophilia A. 2788 31